Outcomes of Definitive Radiotherapy for Bladder Cancer

March 26, 2026 updated by: Heba Ali Elsagheer, Sohag University

Outcomes of Definitive Radiotherapy for Bladder Cancer: Real-World Experience From a Single Center

this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Medical records of all cancer urinary bladder patients will be examined retrospectively. Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy (≥50 Gy to bladder/pelvis); complete treatment records available.

Description

Inclusion Criteria:

  • Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy

Exclusion Criteria:

  • Palliative radiotherapy only; prior radical cystectomy; or incomplete follow-up data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patient with bladder cancer recieving radiotherapy and the treatment related events
Radiation: Radiotherapy followed by chemotherapy
it is observational study for patient recieved defentive radiotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up
Time Frame: one and two year
one and two year
bladder intact events free survival , which is the time from initiation of radical ttt till occurrence of bladder recurrence
Time Frame: one and two year
one and two year
disease free survival , it is time from starting radical ttt till occurrance of 1st recurrence or distant metastasis
Time Frame: one and two years
one and two years

Secondary Outcome Measures

Outcome Measure
Time Frame
adverse events , it is treatment related toxicity and side effects
Time Frame: one year
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

February 5, 2026

First Submitted That Met QC Criteria

March 26, 2026

First Posted (Actual)

March 31, 2026

Study Record Updates

Last Update Posted (Actual)

March 31, 2026

Last Update Submitted That Met QC Criteria

March 26, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-25-12___15PD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bladder Cancer (BC)

Clinical Trials on Radiotherapy followed by chemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe